The CREST Registry study reported on the safety and effectiveness outcomes of microinvasive cyclodialysis clef formation with the CycloPen system, followed by scleral reinforcement with AlloFlo Bio-Tissue implantation, according to Iantrek.

The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the possibility of a sale.

Misconceptions often lead to missed diagnoses.

Catch up on what happened in optometry during the week of February 3-February 7.

Jeffrey Walline, OD, PhD, FAAO, gives an overview of the AAO's 2024 and what to expect in 2025 and beyond.

The dynamic muscle stimulation device is a noninvasive option for patients experiencing lower lid laxity and impaired blinking.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The company sits at spot 43 for “its outstanding performance in areas including unit growth, financial strength and stability, and brand power."

Annual reports of the occurrence of adverse effects associated with the use of cosmetics increased from 2006 to 2018, then decreased from 2018 to 2021.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.

Both patient and provider benefit from reduced contact lens wear cycles.

Optical coherence tomography angiography (OCTA) was performed in all participants; the choroidal and retinal changes were examined and recorded.

All QLS-111 concentrations and dose regimens in both Osprey and Apteryx trials “demonstrated excellent safety and tolerability,” according to the company.

The goal of the agreement is to advance Eleva’s current programs into mid- and late-stage clinical development.

C.Rex is the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.

Wells Fargo, Kirkland & Ellis, and PricewaterHouse Coopers International Limited served as main advisors to VSP Vision on the acquisition.

The partnership will allow Kendra Scott to open availability of its eye wear in the United States starting in September 2025.

The 12-year nationwide cohort found that significant differences in open angle glaucoma risk when assessing the presence of aura were not recorded between the study groups.